STOCK TITAN

LB Pharmaceuticals (LBRX) Stock News

LBRX NASDAQ

LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.

Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) reported a third-quarter net loss of $59.066 million while advancing its LB-102 clinical development program. The loss widened from $3.556 million a year earlier. Research and development expenses rose to $51.516 million from $2.419 million. Cash, cash equivalents and short-term investments totaled $403.760 million at September 30, 2026; the company expects these funds to support operations beyond Q2 2029 under current operating assumptions.

A July private placement raised $150.0 million, with approximately $140.9 million in net proceeds intended to expand LB-102 into new indications. The company expects Phase 3 NOVA-2 schizophrenia results in 1H 2027, bipolar 1 depression results in Q1 2028, and an adjunctive depression trial to begin in early 2027. Susan G. Kozauer and Joseph Miller were appointed Chief Medical Officer and Chief Financial Officer, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
-
Rhea-AI Summary

LB Pharmaceuticals (LBRX) announced that members of its executive team will participate in four upcoming investor conferences.

Fireside chats are scheduled for Craig-Hallum on October 22 at 10:00 a.m. ET, Guggenheim on November 9 at 1:00 p.m. ET, and Stifel on November 12 at 9:20 a.m. ET, all in 2026. The team will also hold investor meetings at these events and Wolfe Research on November 10. Chat webcasts and replays will be available on the company’s investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary

LB Pharmaceuticals (LBRX) presented new preclinical findings on LB-102 and updates on its schizophrenia and bipolar depression clinical programs at ECNP.

In a rat study, LB-102 increased dopamine neurotransmission by reducing inhibition of dopamine release through pre-synaptic D2 autoreceptors. The company sees a potential mechanism for addressing anhedonia, or reduced ability to experience pleasure, and diminished motivation in depression. A previously reported Phase 2 NOVA-1 analysis showed dose-dependent, statistically significant cognitive improvements; a post hoc analysis indicated the benefit was primarily a direct effect of LB-102.

The ongoing Phase 3 NOVA-2 schizophrenia trial and NOVA-3 extension assess efficacy, safety and long-term effectiveness. The ongoing, potentially registrational Phase 2 ILLUMINATE-1 trial evaluates once-daily LB-102 monotherapy in adults with bipolar depression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
Rhea-AI Summary

LB Pharmaceuticals (LBRX) granted stock options to its new chief medical officer and chief financial officer as employment inducements.

Dr. Susan G. Kozauer and Joseph Miller each received options to purchase 200,000 common shares at $37.22 per share, the closing stock price on the October 9, 2026 grant date. The options have a ten-year term and vest over four years: 25% on the first grant anniversary, followed by 1/48th monthly, subject to continuous service through each vesting date. The awards were granted outside the 2025 Equity Incentive Plan, but remain subject to its terms, under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (LBRX) will host an in-person and virtual R&D Day on October 27, 2026, focused on investigational LB-102.

Presentations begin at 2:00 PM ET, featuring Roger S. McIntyre and company management, followed by a live question-and-answer session. Topics include the schizophrenia Phase 3 program, whose topline results the company expects in the first half of 2027, and ongoing pre-commercial planning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (LBRX) has appointed Susan G. Kozauer, M.D. as Chief Medical Officer, adding extensive neuropsychiatric drug development experience to its leadership team.

Dr. Kozauer has more than two decades of clinical development expertise from early-stage studies through regulatory approval, including leading U.S. and global late-stage development of CAPLYTA across adult and pediatric indications at Intra-Cellular Therapies. She most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals, and previously held roles at Premier Research and IQVIA, after practicing as a psychiatrist focused on treatment resistant depression. LB Pharmaceuticals highlighted her role as the company advances toward topline results from its Phase 3 NOVA-2 schizophrenia trial, expected in the first half of 2027, and as it develops LB-102 across multiple neuropsychiatric indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
none
Rhea-AI Summary

LB Pharmaceuticals (LBRX)/b) will present at several investor events in September 2026, including conferences hosted by Wells Fargo, H.C. Wainwright, and TD Cowen.The company will hold in-person 1x1 meetings at Wells Fargo’s 21st Annual Healthcare Conference on September 9 in Boston, virtual presentations and 1x1 meetings at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, and a virtual fireside chat during TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23. Webcasts and replays will be accessible via the Investors/Events section of LB Pharmaceuticals’ website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (LBRX) appointed Joseph Miller as Chief Financial Officer, bringing more than 20 years of biopharmaceutical finance and operational leadership experience to the company.

The company highlights Miller’s track record in scaling infrastructure and teams to support organizational growth, commercialization and long-term value creation. Management ties his appointment to a “potentially transformative period” as LB Pharmaceuticals approaches pivotal NOVA-2 clinical trial results and continues preparations for the potential launch of LB-102 in schizophrenia.

Miller most recently served as CFO of Aurinia Pharmaceuticals, where he built and scaled finance and operations during the transition from late-stage development to the commercial launch of LUPKYNIS for active lupus nephritis, overseeing revenue growth, profitability and an ex-U.S. licensing and collaboration agreement with Otsuka Pharmaceutical. His prior roles include CFO and senior leadership positions at Avalo Therapeutics, Sucampo Pharmaceuticals, QIAGEN, Eppendorf and KPMG LLP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
none
-
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) reported second quarter 2026 results and a corporate update centered on lead candidate LB-102 for schizophrenia and mood disorders. Enrollment in the pivotal Phase 3 NOVA-2 schizophrenia trial is ahead of plan, with topline data now expected in the first half of 2027, followed by a planned pre-NDA FDA meeting in the second half of 2027. A 52-week open-label safety study (NOVA-3) is enrolling, and the Phase 2 bipolar depression trial ILLUMINATE-1 targets topline data in Q1 2028, with a Phase 2 adjunctive MDD study expected to start in early 2027 and read out in the first half of 2029.

Q2 2026 research and development expenses rose to $44.1 million and general and administrative expenses to $9.8 million, driving a net loss of $51.6 million. As of June 30, 2026, cash, cash equivalents and marketable securities were $327.8 million, excluding net proceeds from a $150.0 million July 2026 private placement, which the company expects will fund operations beyond the second quarter of 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement for a private placement of 3,577,560 common shares and pre-funded warrants to purchase up to 715,513 additional shares at a purchase price of $34.94 per share (and $34.9399 per pre-funded warrant), for anticipated gross proceeds of about $150 million before expenses.

The financing is expected to close on or about July 30, 2026, subject to customary conditions, and includes several new and existing institutional investors. According to LB Pharmaceuticals, net proceeds will fund pipeline expansion of LB-102 into new indications and support working capital and general corporate purposes. The securities are being issued in a unregistered private placement, and the company agreed to file a registration statement to register the resale of the issued shares and the shares underlying the pre-funded warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.62%
Tags
private placement

FAQ

What is the current stock price of LB Pharmaceuticals (LBRX)?

LB Pharmaceuticals (LBRX) last closed at $38.85.

What is the market cap of LB Pharmaceuticals (LBRX)?

The market cap of LB Pharmaceuticals (LBRX) is approximately $1.3B.